¸¸¼ººñ¼¼±Õ¼ºÀü¸³¼±¿° Á㠸𵨿¡¼­ Ç÷ηÎź´ÑÀÇ Ç׿° È¿°ú
Anti-Inflammatory Effect of Phlorotannin on Chronic Nonbacterial Prostatitis in a Rat Model

´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸÁö 2014³â 9±Ç 2È£ p.86 ~ p.92

Á¤À±¼®(Jung Yun-Seok) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ºñ´¢±â°úÇб³½Ç
Á¶¿ëÇö(Cho Yong-Hyun) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ºñ´¢±â°úÇб³½Ç
ÇÑâÈñ(Han Chang-Hee) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

Purpose: Chronic nonbacterial prostatitis and chronic pelvic pain syndrome account for 90-95% of all prostatitis. Little is known about its pathophysiology, thus, various treatments are used. Ecklonia cava, a seaweed, is a member of the brown algae family; many recent reports have demonstrated that its extract containing phlorotannin has anti-oxidative and anti-inflammatory properties. Using the hormone-induced prostatitis rat model, we investigated the anti-inflammatory effects of E. cava extracts via its anti-oxidative process on chronic nonbacterial prostatitis.

Materials and Methods: Forty, 10-week-old male white Wistar rats were utilized, and divided equally into the following five groups: 1) control, 2) E. cava-fed, 3) hormone-induced prostatitis (HIP), 4) E. cava-treated HIP, and 5) nonsteroidal anti-inflammatory drug (NSAID)-treated HIP.

Results: The results showed statistically-significant improvement in the tissue response to the hormone-induced inflammation among the E. cava-treated and NSAID-treated groups (p£¼0.05). Lower malonedialdehyde levels were observed in the group with E. cava-treated HIP than with HIP alone, which was statistically significant. We believe that this supports the anti-oxidative properties of E. cava.

Conclusions: This study demonstrates that phlorotannin has anti-inflammatory properties via its anti-oxidative process, which we expect to play an important role in prevention and as an adjuvant therapy for chronic nonbacterial prostatitis.

Ű¿öµå

Prostatitis, Estrogens, Anti-inflammatory agents
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå